BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 17869975)

  • 1. Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trial.
    DiNubile MJ; Lupinacci RJ; Strohmaier KM; Sable CA; Kartsonis NA
    J Crit Care; 2007 Sep; 22(3):237-44. PubMed ID: 17869975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Invasive candidiasis in cancer patients: observations from a randomized clinical trial.
    DiNubile MJ; Hille D; Sable CA; Kartsonis NA
    J Infect; 2005 Jun; 50(5):443-9. PubMed ID: 15907554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of caspofungin and amphotericin B for invasive candidiasis.
    Mora-Duarte J; Betts R; Rotstein C; Colombo AL; Thompson-Moya L; Smietana J; Lupinacci R; Sable C; Kartsonis N; Perfect J;
    N Engl J Med; 2002 Dec; 347(25):2020-9. PubMed ID: 12490683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B.
    Dupont BF; Lortholary O; Ostrosky-Zeichner L; Stucker F; Yeldandi V
    Crit Care; 2009; 13(5):R159. PubMed ID: 19804626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis.
    Betts RF; Nucci M; Talwar D; Gareca M; Queiroz-Telles F; Bedimo RJ; Herbrecht R; Ruiz-Palacios G; Young JA; Baddley JW; Strohmaier KM; Tucker KA; Taylor AF; Kartsonis NA;
    Clin Infect Dis; 2009 Jun; 48(12):1676-84. PubMed ID: 19419331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006).
    Leroy O; Gangneux JP; Montravers P; Mira JP; Gouin F; Sollet JP; Carlet J; Reynes J; Rosenheim M; Regnier B; Lortholary O;
    Crit Care Med; 2009 May; 37(5):1612-8. PubMed ID: 19325476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis.
    Keating G; Figgitt D
    Drugs; 2003; 63(20):2235-63. PubMed ID: 14498760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia.
    Maertens JA; Madero L; Reilly AF; Lehrnbecher T; Groll AH; Jafri HS; Green M; Nania JJ; Bourque MR; Wise BA; Strohmaier KM; Taylor AF; Kartsonis NA; Chow JW; Arndt CA; DePauw BE; Walsh TJ;
    Pediatr Infect Dis J; 2010 May; 29(5):415-20. PubMed ID: 20431381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of micafungin for treatment of serious Candida infections in patients with or without malignant disease.
    Cornely OA; Marty FM; Stucker F; Pappas PG; Ullmann AJ
    Mycoses; 2011 Nov; 54(6):e838-47. PubMed ID: 21668522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caspofungin for the treatment of less common forms of invasive candidiasis.
    Cornely OA; Lasso M; Betts R; Klimko N; Vazquez J; Dobb G; Velez J; Williams-Diaz A; Lipka J; Taylor A; Sable C; Kartsonis N
    J Antimicrob Chemother; 2007 Aug; 60(2):363-9. PubMed ID: 17526917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis.
    Colombo AL; Perfect J; DiNubile M; Bartizal K; Motyl M; Hicks P; Lupinacci R; Sable C; Kartsonis N
    Eur J Clin Microbiol Infect Dis; 2003 Aug; 22(8):470-4. PubMed ID: 12884068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Refractory neonatal candidemia and high-dose micafungin pharmacotherapy.
    Natarajan G; Lulic-Botica M; Aranda JV
    J Perinatol; 2009 Nov; 29(11):738-43. PubMed ID: 19776753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting.
    Ostrosky-Zeichner L; Shoham S; Vazquez J; Reboli A; Betts R; Barron MA; Schuster M; Judson MA; Revankar SG; Caeiro JP; Mangino JE; Mushatt D; Bedimo R; Freifeld A; Nguyen MH; Kauffman CA; Dismukes WE; Westfall AO; Deerman JB; Wood C; Sobel JD; Pappas PG
    Clin Infect Dis; 2014 May; 58(9):1219-26. PubMed ID: 24550378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.
    Pappas PG; Rotstein CM; Betts RF; Nucci M; Talwar D; De Waele JJ; Vazquez JA; Dupont BF; Horn DL; Ostrosky-Zeichner L; Reboli AC; Suh B; Digumarti R; Wu C; Kovanda LL; Arnold LJ; Buell DN
    Clin Infect Dis; 2007 Oct; 45(7):883-93. PubMed ID: 17806055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment with caspofungin of refractory Candida krusei candidemia in a very low birth weight preterm infant.
    Natale F; Castronovo A; Regoli D; De Curtis M; Manzoni P
    Pediatr Infect Dis J; 2009 May; 28(5):452. PubMed ID: 19295457
    [No Abstract]   [Full Text] [Related]  

  • 16. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
    Walsh TJ; Teppler H; Donowitz GR; Maertens JA; Baden LR; Dmoszynska A; Cornely OA; Bourque MR; Lupinacci RJ; Sable CA; dePauw BE
    N Engl J Med; 2004 Sep; 351(14):1391-402. PubMed ID: 15459300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients.
    Zaoutis TE; Jafri HS; Huang LM; Locatelli F; Barzilai A; Ebell W; Steinbach WJ; Bradley J; Lieberman JM; Hsiao CC; Seibel N; Laws HJ; Gamba M; Petrecz M; Taylor AF; Strohmaier KM; Chow JW; Kartsonis NA; Ngai AL
    Pediatrics; 2009 Mar; 123(3):877-84. PubMed ID: 19255017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial.
    Queiroz-Telles F; Berezin E; Leverger G; Freire A; van der Vyver A; Chotpitayasunondh T; Konja J; Diekmann-Berndt H; Koblinger S; Groll AH; Arrieta A;
    Pediatr Infect Dis J; 2008 Sep; 27(9):820-6. PubMed ID: 18679151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, prospective study of caspofungin vs. amphotericin B for the treatment of invasive candidiasis in newborn infants.
    Mohamed WA; Ismail M
    J Trop Pediatr; 2012 Feb; 58(1):25-30. PubMed ID: 21355042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Micafungin in invasive candidiasis among oncohematological patients].
    Jarque I; Angel Sanz M
    Rev Iberoam Micol; 2009 Mar; 26(1):75-7. PubMed ID: 19463282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.